Novo Nordisk A/S $NVO Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 12.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 462,940 shares of the company’s stock after selling 63,294 shares during the period. PNC Financial Services Group Inc.’s holdings in Novo Nordisk A/S were worth $25,689,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of NVO. Jennison Associates LLC grew its holdings in shares of Novo Nordisk A/S by 0.3% during the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock valued at $1,303,466,000 after purchasing an additional 63,341 shares during the last quarter. Loomis Sayles & Co. L P lifted its stake in Novo Nordisk A/S by 1.5% in the second quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock valued at $867,998,000 after buying an additional 187,789 shares during the last quarter. Folketrygdfondet boosted its holdings in shares of Novo Nordisk A/S by 1.2% during the third quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock valued at $566,659,000 after acquiring an additional 117,370 shares during the period. Sustainable Growth Advisers LP grew its position in shares of Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after acquiring an additional 649,390 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Novo Nordisk A/S by 0.8% in the 2nd quarter. State Street Corp now owns 6,047,683 shares of the company’s stock worth $418,231,000 after acquiring an additional 47,430 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: EU approves higher Wegovy dose — the European Commission approved a 7.2 mg maintenance dose of Wegovy after a study showing ~21% average weight loss over ~18 months, which should support uptake and revenue in EU markets. Article Title
• Positive Sentiment: Pipeline beef-up — Novo initiated/updated a Phase‑2 study for UBT251 in obesity, broadening its obesity pipeline and signalling continued R&D investment that could produce future revenue streams. Article Title
• Positive Sentiment: Promising next‑gen drugs — coverage notes a new diabetes candidate that may outperform current semaglutide medicines, offering medium‑term upside if clinical/launch execution succeeds. Article Title
• Positive Sentiment: Share repurchase program — Novo launched repurchases as part of a DKK 15 billion program, which can support EPS and share demand. Article Title
• Neutral Sentiment: Analyst/valuation viewpoint — commentary suggests the stock could have upside due to a materially lower forward P/E and the potential for a sales surprise later this year, but this view depends on execution and a recovery in 2027. Article Title
• Negative Sentiment: Near‑term demand and guidance concerns — coverage highlights a recent ~21% drop over the past month tied to weak 2026 guidance, slowing semaglutide sales and rising competition, which are primary reasons the stock is under pressure today. Article Title

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. HSBC reissued a “hold” rating and set a $54.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, January 22nd. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Finally, Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Seven research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $56.07.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $49.30 on Wednesday. The company has a 50-day moving average of $53.86 and a 200-day moving average of $53.27. The firm has a market cap of $220.12 billion, a price-to-earnings ratio of 14.21 and a beta of 0.67. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is 23.63%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.